Kenya has recently initiated the distribution of lenacapavir, a promising new injectable medication hailed as a potential game-changer in the fight against HIV. While this rollout offers hope for many, critical gaps remain in access, particularly for populations in high-risk areas such as Kibera. These disparities highlight the challenges of ensuring equitable healthcare in the pursuit of public health advancements.
Lenacapavir: A New Hope in HIV Prevention
Last month, Kenya became one of the pioneering nations to launch the distribution of lenacapavir, a drug that scientists liken to a breakthrough in HIV prevention. This injectable treatment is considered a significant advancement, particularly for the 1.4 million Kenyans currently living with HIV, as well as for the larger population at risk of infection.
The government aims to substantially reduce new HIV infections by 2030 through this programme. However, the initial rollout has excluded Kibera, one of Africa’s largest informal settlements, where the HIV prevalence rate stands at around 12 per cent, significantly higher than the five per cent recorded in more affluent urban areas. This oversight raises pressing questions about the effectiveness of the programme in reaching those who need it most.
Exclusion from the Rollout: A Barrier to Access
The initial phase of lenacapavir’s distribution will see approximately 21,000 doses allocated across 152 health facilities in 15 high-burden counties. Notably absent from this list is the Tabitha Medical Clinic, operated by CFK Africa, a community-based organisation that has long served the Kibera population. Jeffrey Okoro, the organisation’s chief executive, expresses concern over this exclusion, stating, “I’ve seen firsthand how devastating HIV and AIDS can be… lenacapavir could be a game-changer. Right now, it’s not reaching the people who would benefit most.”
Although residents have the option to travel to designated health facilities in other parts of Nairobi, the logistical challenges are considerable. The nearest approved sites are located between 1.5 and 3.5 miles away, and the cost of transportation can range from 220 to 380 Kenyan shillings (approximately £1.30 to £2.20)—a substantial expense for those living on less than £1.50 a day. For many, this means choosing between transport and basic necessities.
The Financial Implications and Future Accessibility
Currently, lenacapavir is being offered for free during this initial rollout. However, there are concerns regarding its long-term accessibility. Health officials have indicated that if the programme scales up, the annual cost for lenacapavir could reach around 7,800 Kenyan shillings, which, while subsidised, still represents a significant financial burden for low-income families. Agreements with organisations like the Clinton Health Access Initiative and the Gates Foundation aim to drive prices down to approximately £30 per patient annually, but this relies on the availability of generic versions expected only by 2027.
Antonio Flores, a senior HIV adviser at Médecins Sans Frontières, warns that without intentional policy measures, the distribution of such medical advancements may remain inequitable. He points out that the current rollout may not adequately consider the structural barriers that hinder access for vulnerable communities.
A Call for Community-Based Solutions
Kenya’s health authorities maintain that this phase is merely the beginning, yet the efficacy of the programme will hinge on true access for those most at risk. Past initiatives aimed at improving retention in HIV treatment have illustrated the persistent barriers faced by communities. For instance, a recent trial that offered non-cash incentives alongside psychosocial support yielded no significant increase in patient retention during the first six months.
Okoro emphasises the need for a community-centric approach: “You could attach someone to a youth centre, follow up with them, remind them when their next injection is due. That’s how you build something that actually works.” Engaging existing networks of health promoters and local organisations could facilitate better access and ensure that patients return for their necessary follow-ups.
At a health centre included in the rollout, patients like Teresia Wanjiku express enthusiasm for lenacapavir, describing it as a long-awaited relief from the daily burden of taking pills. “I have been waiting for this for many years. It is much easier than taking pills every day,” she says, reflecting the hope this innovative treatment brings to those who can access it.
Why it Matters
The introduction of lenacapavir represents a significant step forward in the ongoing battle against HIV. However, the failure to include high-risk communities like Kibera in the initial rollout underscores a critical flaw in health equity efforts. As long as accessible treatment remains out of reach for the most vulnerable populations, the promise of this medical advancement risks being unfulfilled. Ensuring that health innovations are delivered equitably is crucial not only for individual health outcomes but for the broader goal of eradicating HIV as a public health threat.
